Vaccine effectiveness and longevity in UK

Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK https://www.ndm.ox.ac.uk/covid-19/covid-19-infection-survey/results/new-studies https://www.ndm.ox.ac.uk/files/coronavirus/covid-19-infection-survey/finalfinalcombinedve20210816.pdf N = 384,543 Households, 221,909 Obtaining two vaccine doses remains the most effective way to ensure protection against Delta With Delta, Pfizer-BioNTech and Oxford-AstraZeneca vaccines still offer good protection against new infections but effectiveness is reduced compared with Alpha However, Delta infections after two vaccine doses had similar peak levels of virus to those in unvaccinated people (with the Alpha variant, peak virus levels in those infected post-vaccination were much lower) Two doses of either vaccine still provided at least the same level of protection as having had COVID-19 through natural infection People who had been vaccinated after already being infected with COVID-19 had even more protection than vaccinated individuals who had not had COVID-19 before Two doses of Pfizer-BioNTech have greater initial effectiveness against new COVID-19 infections but this declines faster compared with two doses of Oxford-AstraZeneca After four to five months, effectiveness of these two vaccines similar however, long-term effects need to be studied The time between doses does not affect effectiveness in preventing new infections Younger people have even more protection from vaccination than older people UK, third shots https://www.bbc.co.uk/news/live/uk-58266043 Prof Peter Openshaw New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG We can't just look at the antibody levels and think that that equates to levels of protection It still seems that you get a lot of protection from these vaccines, even if the antibody levels have drifted down to some sort of stable level Learn more about your ad choices. Visit megaphone.fm/adchoices